L. Hammond

发表

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

M. Beeram, E. Rowinsky, L. Hammond, 2007, Clinical Cancer Research.

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.

G. Weiss, D. V. Von Hoff, H. Burris, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

A. Tolcher, C. Takimoto, E. Rowinsky, 2005, Clinical Cancer Research.

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

R. Goldberg, L. Schaaf, M. Rothenberg, 2006, Clinical Cancer Research.

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms

G. Weiss, D. V. Von Hoff, L. Smith, 2004, Clinical Cancer Research.

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

G. Weiss, D. V. Von Hoff, S. Baker, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies

G. Weiss, S. Baker, D. V. Hoff, 1999 .

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

A. Tolcher, I. Thompson, L. Smetzer, 2004, Clinical Cancer Research.

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 2000, European journal of cancer.

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

L. Denis, A. DeCillis, E. Rowinsky, 2004, Clinical Cancer Research.

APhase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

M. Beeram, E. Rowinsky, L. Hammond, 2007 .

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

A. Tolcher, C. Takimoto, A. Patnaik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.

L. Hammond, 2003, Clinical lung cancer.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

R. Herbst, D. Carbone, S. Solomon, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

A. Tolcher, T. Whiteside, J. Stephenson, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

J. Rigas, R. Perez-soler, G. Clark, 2003 .

An image worth a thousand lives?

Charles R. Thomas, S. Cavanaugh, L. Hammond, 2004, Nature Biotechnology.

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

C. Takimoto, A. Patnaik, E. Rowinsky, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

A. Tolcher, C. Takimoto, D. V. Von Hoff, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

A. Tolcher, C. Takimoto, L. Smith, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

A. Tolcher, C. Takimoto, L. Smith, 2008, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

M. Hidalgo, G. Weiss, D. V. Von Hoff, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.

M. Hidalgo, D. V. Von Hoff, A. Patnaik, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005 .

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005, Clinical Cancer Research.

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

A. Tolcher, A. Patnaik, M. Mita, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

M. Hidalgo, G. Weiss, C. Britten, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Localized bowel vasculitis: postoperative cyclophosphamide or not?

K. Raza, P. Bacon, A. Exley, 1999, Arthritis and rheumatism.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

M. Hidalgo, L. Smith, E. Rowinsky, 2001 .

A Phase I and Pharmacokinetic Study of Squalamine , an Aminosterol Angiogenesis Inhibitor 1

A. Tolcher, C. Takimoto, A. Patnaik, 2003 .

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

P. Bonate, G. Weiss, A. Mita, 2006, Clinical Cancer Research.

Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors

P. Bonate, A. Mita, E. Rowinsky, 2006 .

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

A. Tolcher, C. Takimoto, A. Patnaik, 2004, Clinical Cancer Research.

ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC).

K. Takeshita, J. Schiller, J. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

A. Tolcher, P. LoRusso, A. Patnaik, 2004, Clinical Cancer Research.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

C. Takimoto, D. V. Von Hoff, L. Smetzer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331

C. Britten, S. Baker, E. Douglass, 1999 .

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.

M. Hidalgo, D. V. Von Hoff, L. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cantuzumab M ertansine, a M aytansinoid I mmunoconjugate Directed t o t he C anAg A ntigen: A P hase I , P harmacokinetic, and B iologic C orrelative S tudy

A. Tolcher, C. Takimoto, L. Smith, 2003 .

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, E. Hersh, L. Hammond, 2005, Clinical Cancer Research.

APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors

P. Bonate, E. Hersh, L. Hammond, 2005 .

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.

D. V. Von Hoff, G. Weiss, S. Baker, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J. Rigas, R. Perez-soler, G. Clark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacologic S tudy o f O SI-774, a n Epidermal G rowth F actor R eceptor T yrosine K inase Inhibitor, i n P atients W ith A dvanced S olid M alignancies

M. Hidalgo, J. Nemunaitis, C. Takimoto, 2001 .

A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.

G. Weiss, D. V. Von Hoff, H. Burris, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors 1

G. Weiss, H. Burris, S. Baker, 1999 .

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

M. Hidalgo, A. Tolcher, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.

D. V. Von Hoff, A. Patnaik, L. Hammond, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma

S. O’Day, E. Hersh, J. Stephenson, 2004 .

Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma.

S. O’Day, E. Hersh, J. Stephenson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

M. Hidalgo, L. Siu, M. Brattain, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

M. Kris, M. Ranson, V. Miller, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patientswith Advanced SolidTumors

A. Tolcher, C. Takimoto, E. Rowinsky, 2005 .

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

E K Rowinsky, M. Hidalgo, A. Tolcher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring the mechanisms of action of FB642 at the cellular level

D. V. Von Hoff, L. Hammond, E. Izbicka, 2001, Journal of Cancer Research and Clinical Oncology.

Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Weiss, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

D. V. Von Hoff, C. Britten, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of SAM 486 A , a Novel Polyamine Biosynthesis Inhibitor , Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies 1

M. Hidalgo, G. Weiss, G. Clark, 2002 .

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acute retinal toxicity from the novel anti-tumor agent, Irofulven

R. Melendez, E. Rowinsky, L. Hammond, 2004, Documenta Ophthalmologica.

Renal pathological findings in infective endocarditis.

A Majumdar, W. Littler, G. Lipkin, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.

A. Lockhart, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

E K Rowinsky, D. V. Von Hoff, E. Rowinsky, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

M. Hidalgo, A. Tolcher, M. Beeram, 2006, Clinical Cancer Research.

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Manuel Hidalgo, M. Hidalgo, A. Tolcher, 2004, Clinical Cancer Research.

HER-Targeted Tyrosine-Kinase Inhibitors

J. Baselga, L. Hammond, 2002, Oncology.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

A. Tolcher, C. Geyer, L. Denis, 2003, British Journal of Cancer.

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

M. Kris, J. Baselga, R. Herbst, 2000 .

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

A. Tolcher, G. Weiss, C. Takimoto, 2007, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

A. Tolcher, C. Takimoto, L. Denis, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternative dosing schedules for irinotecan.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 1998, Oncology.

Positron emission tomography (PET): Expanding the horizons of oncology drug development

Charles R. Thomas, Paul Jerabek, P. Jerabek, 2003, Investigational New Drugs.

A P hase I a nd P harmacokinetic S tudy o f P egylated Camptothecin a s a 1 -Hour I nfusion E very 3 W eeks i n P atients With A dvanced S olid M alignancies

A. Tolcher, C. Takimoto, L. Denis, 2003 .

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

A. Tolcher, C. Geyer, C. Takimoto, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

A. Tolcher, C. Geyer, D. V. Von Hoff, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

M. Hidalgo, G. Weiss, A. Patnaik, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

A. Tolcher, C. Takimoto, A. Patnaik, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Clark, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.

T. Hander, D. V. Von Hoff, H. Burris, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

J. Geraghty, E. McDermott, C. Quinn, 2018, British Journal of Cancer.

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.

M. Mita, E. Rowinsky, L. Hammond, 2004, Journal of Clinical Oncology.

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

D. V. Von Hoff, S. Baker, M. Villalona-Calero, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacologic S tudy o f P N401 a nd F luorouracil in P atients W ith A dvanced S olid M alignancies

M. Hidalgo, G. Weiss, M. Villalona-Calero, 2000 .

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors.

E. Hersh, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC)

K. Takeshita, J. Schiller, J. Crawford, 2004 .